Prime Highlights :
- Avammune Therapeutics secures $12 million in capital from Capital 2B.
- Capital to develop low-cost oral drugs for cancer and autoimmune disease.
Key Facts :
- Avammune’s platform leverages innate immunity to develop new, non-biologic therapies.
- Clinical trials will start within a year.
Key Background :
Avammune Therapeutics, a healthtech startup based in Pune, raised $12 million in a fresh round of funding, led by early-stage venture capital firm Capital 2B. Other investors also joined the round, which was not disclosed. The funds will be used strategically to expand Avammune’s research and development capabilities in the field of immuno-oncology and autoimmune diseases.
Avammune is leading the way to leverage the body’s own endogenous immune system to develop oral, small-molecule drugs that are more convenient and less expensive than conventional biologics. These drugs cure a broad range of diseases, such as cancer and autoimmune diseases, for which existing treatments are too expensive or have ghastly toxicity profiles.
Avammune’s technology has demonstrated potential in a variety of preclinical animal models to date and will be poised to move ahead with full-scale safety trials. Avammune intends to move preclinical studies to their conclusion and finish its initial human clinical trials within the next near term with the new funding. Avammune is also actively engaged in discussions with several leading pharmaceutical and biotechnology industry companies on establishing aggressive strategic partnership and co-development agreements.
Anchor investor Capital 2B, a specialized investment company that invests in technology-based companies in healthcare and deep-tech sectors, invested in Avammune as part of its broader strategic investment direction to invest in life science innovation breakthroughs with worldwide scaleability.
The achievement is a tremendous milestone for Avammune since it is working towards transforming the treatment of dangerous and long-term diseases. With its emphasis on oral immunotherapy, the company not only simplifies treatment but also increases the accessibility of patients globally.
Read More: Turkessa Antrum: An Astute Forerunner and a Firm Believer in Change
